A prospective, open-label trial of olanzapine in adolescents with schizophrenia

Robert L Findling, Nora K. McNamara, Eric A. Youngstrom, Lisa A. Branicky, Christine A. Demeter, S. Charles Schulz

Research output: Contribution to journalArticle

Abstract

Background: Olanzapine is an atypical antipsychotic that has efficacy in adults with psychotic disorders. This preliminary study examined the effectiveness of olanzapine in adolescents with schizophrenia or its related conditions. Method: Adolescents aged 12-17 years (inclusive) with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder were enrolled in this 8-week, open-label, outpatient study. The Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions Scale (CGI), and the Children's Global Assessment Scale (CGAS) were administered as outcome measures. Extrapyramidal side effects were assessed at each visit. Olanzapine was initiated at a dose of 2.5 mg/day and could be increased to a maximum total daily dose of 20 mg. Results: Sixteen participants with a mean age of 13.8 (SD = 1.5) years were treated. Significant improvements were found in the PANSS, CGI severity, and CGAS scores. Reductions in both positive and negative symptoms were found. Increased appetite and sedation were the most frequently reported side effects. Two subjects required treatment for extrapyramidal side effects. Conclusions: Psychotic symptoms significantiy improved during study. Overall, olanzapine was well tolerated. Future studies are needed to confirm these findings, to assess long-term treatment outcomes, and to compare the effectiveness of olanzapine with that of other antipsychotics.

Original languageEnglish (US)
Pages (from-to)170-175
Number of pages6
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume42
Issue number2
DOIs
StatePublished - Feb 2003
Externally publishedYes

Fingerprint

olanzapine
Schizophrenia
Psychotic Disorders
Antipsychotic Agents
Appetite
Outpatients
Outcome Assessment (Health Care)

Keywords

  • Adolescent
  • Olanzapine
  • Schizoaffective disorder
  • Schizophrenia
  • Schizophreniform disorder

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

A prospective, open-label trial of olanzapine in adolescents with schizophrenia. / Findling, Robert L; McNamara, Nora K.; Youngstrom, Eric A.; Branicky, Lisa A.; Demeter, Christine A.; Schulz, S. Charles.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 42, No. 2, 02.2003, p. 170-175.

Research output: Contribution to journalArticle

Findling, Robert L ; McNamara, Nora K. ; Youngstrom, Eric A. ; Branicky, Lisa A. ; Demeter, Christine A. ; Schulz, S. Charles. / A prospective, open-label trial of olanzapine in adolescents with schizophrenia. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2003 ; Vol. 42, No. 2. pp. 170-175.
@article{9f067fb2e32c4a598de471e4ef0e7b3b,
title = "A prospective, open-label trial of olanzapine in adolescents with schizophrenia",
abstract = "Background: Olanzapine is an atypical antipsychotic that has efficacy in adults with psychotic disorders. This preliminary study examined the effectiveness of olanzapine in adolescents with schizophrenia or its related conditions. Method: Adolescents aged 12-17 years (inclusive) with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder were enrolled in this 8-week, open-label, outpatient study. The Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions Scale (CGI), and the Children's Global Assessment Scale (CGAS) were administered as outcome measures. Extrapyramidal side effects were assessed at each visit. Olanzapine was initiated at a dose of 2.5 mg/day and could be increased to a maximum total daily dose of 20 mg. Results: Sixteen participants with a mean age of 13.8 (SD = 1.5) years were treated. Significant improvements were found in the PANSS, CGI severity, and CGAS scores. Reductions in both positive and negative symptoms were found. Increased appetite and sedation were the most frequently reported side effects. Two subjects required treatment for extrapyramidal side effects. Conclusions: Psychotic symptoms significantiy improved during study. Overall, olanzapine was well tolerated. Future studies are needed to confirm these findings, to assess long-term treatment outcomes, and to compare the effectiveness of olanzapine with that of other antipsychotics.",
keywords = "Adolescent, Olanzapine, Schizoaffective disorder, Schizophrenia, Schizophreniform disorder",
author = "Findling, {Robert L} and McNamara, {Nora K.} and Youngstrom, {Eric A.} and Branicky, {Lisa A.} and Demeter, {Christine A.} and Schulz, {S. Charles}",
year = "2003",
month = "2",
doi = "10.1097/00004583-200302000-00010",
language = "English (US)",
volume = "42",
pages = "170--175",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - A prospective, open-label trial of olanzapine in adolescents with schizophrenia

AU - Findling, Robert L

AU - McNamara, Nora K.

AU - Youngstrom, Eric A.

AU - Branicky, Lisa A.

AU - Demeter, Christine A.

AU - Schulz, S. Charles

PY - 2003/2

Y1 - 2003/2

N2 - Background: Olanzapine is an atypical antipsychotic that has efficacy in adults with psychotic disorders. This preliminary study examined the effectiveness of olanzapine in adolescents with schizophrenia or its related conditions. Method: Adolescents aged 12-17 years (inclusive) with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder were enrolled in this 8-week, open-label, outpatient study. The Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions Scale (CGI), and the Children's Global Assessment Scale (CGAS) were administered as outcome measures. Extrapyramidal side effects were assessed at each visit. Olanzapine was initiated at a dose of 2.5 mg/day and could be increased to a maximum total daily dose of 20 mg. Results: Sixteen participants with a mean age of 13.8 (SD = 1.5) years were treated. Significant improvements were found in the PANSS, CGI severity, and CGAS scores. Reductions in both positive and negative symptoms were found. Increased appetite and sedation were the most frequently reported side effects. Two subjects required treatment for extrapyramidal side effects. Conclusions: Psychotic symptoms significantiy improved during study. Overall, olanzapine was well tolerated. Future studies are needed to confirm these findings, to assess long-term treatment outcomes, and to compare the effectiveness of olanzapine with that of other antipsychotics.

AB - Background: Olanzapine is an atypical antipsychotic that has efficacy in adults with psychotic disorders. This preliminary study examined the effectiveness of olanzapine in adolescents with schizophrenia or its related conditions. Method: Adolescents aged 12-17 years (inclusive) with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder were enrolled in this 8-week, open-label, outpatient study. The Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions Scale (CGI), and the Children's Global Assessment Scale (CGAS) were administered as outcome measures. Extrapyramidal side effects were assessed at each visit. Olanzapine was initiated at a dose of 2.5 mg/day and could be increased to a maximum total daily dose of 20 mg. Results: Sixteen participants with a mean age of 13.8 (SD = 1.5) years were treated. Significant improvements were found in the PANSS, CGI severity, and CGAS scores. Reductions in both positive and negative symptoms were found. Increased appetite and sedation were the most frequently reported side effects. Two subjects required treatment for extrapyramidal side effects. Conclusions: Psychotic symptoms significantiy improved during study. Overall, olanzapine was well tolerated. Future studies are needed to confirm these findings, to assess long-term treatment outcomes, and to compare the effectiveness of olanzapine with that of other antipsychotics.

KW - Adolescent

KW - Olanzapine

KW - Schizoaffective disorder

KW - Schizophrenia

KW - Schizophreniform disorder

UR - http://www.scopus.com/inward/record.url?scp=0037313928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037313928&partnerID=8YFLogxK

U2 - 10.1097/00004583-200302000-00010

DO - 10.1097/00004583-200302000-00010

M3 - Article

C2 - 12544176

AN - SCOPUS:0037313928

VL - 42

SP - 170

EP - 175

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 2

ER -